163 related articles for article (PubMed ID: 27598117)
21. Isotopically Labeled Desthiobiotin Azide (isoDTB) Tags Enable Global Profiling of the Bacterial Cysteinome.
Zanon PRA; Lewald L; Hacker SM
Angew Chem Int Ed Engl; 2020 Feb; 59(7):2829-2836. PubMed ID: 31782878
[TBL] [Abstract][Full Text] [Related]
22. Systematic Studies on the Protocol and Criteria for Selecting a Covalent Docking Tool.
Wen C; Yan X; Gu Q; Du J; Wu D; Lu Y; Zhou H; Xu J
Molecules; 2019 Jun; 24(11):. PubMed ID: 31185706
[TBL] [Abstract][Full Text] [Related]
23. Cysteine tagging for MS-based proteomics.
Giron P; Dayon L; Sanchez JC
Mass Spectrom Rev; 2011; 30(3):366-95. PubMed ID: 21500242
[TBL] [Abstract][Full Text] [Related]
24. Sample multiplexing with cysteine-selective approaches: cysDML and cPILOT.
Gu L; Evans AR; Robinson RA
J Am Soc Mass Spectrom; 2015 Apr; 26(4):615-30. PubMed ID: 25588721
[TBL] [Abstract][Full Text] [Related]
25. Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target.
Roberts AM; Miyamoto DK; Huffman TR; Bateman LA; Ives AN; Akopian D; Heslin MJ; Contreras CM; Rape M; Skibola CF; Nomura DK
ACS Chem Biol; 2017 Apr; 12(4):899-904. PubMed ID: 28186401
[TBL] [Abstract][Full Text] [Related]
26. CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites.
Cimermancic P; Weinkam P; Rettenmaier TJ; Bichmann L; Keedy DA; Woldeyes RA; Schneidman-Duhovny D; Demerdash ON; Mitchell JC; Wells JA; Fraser JS; Sali A
J Mol Biol; 2016 Feb; 428(4):709-719. PubMed ID: 26854760
[TBL] [Abstract][Full Text] [Related]
27. A proteome-wide atlas of lysine-reactive chemistry.
Abbasov ME; Kavanagh ME; Ichu TA; Lazear MR; Tao Y; Crowley VM; Am Ende CW; Hacker SM; Ho J; Dix MM; Suciu R; Hayward MM; Kiessling LL; Cravatt BF
Nat Chem; 2021 Nov; 13(11):1081-1092. PubMed ID: 34504315
[TBL] [Abstract][Full Text] [Related]
28. Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs.
Wang Y; Dix MM; Bianco G; Remsberg JR; Lee HY; Kalocsay M; Gygi SP; Forli S; Vite G; Lawrence RM; Parker CG; Cravatt BF
Nat Chem; 2019 Dec; 11(12):1113-1123. PubMed ID: 31659311
[TBL] [Abstract][Full Text] [Related]
29. Identification of a New Type of Covalent PPARγ Agonist using a Ligand-Linking Strategy.
Ohtera A; Miyamae Y; Yoshida K; Maejima K; Akita T; Kakizuka A; Irie K; Masuda S; Kambe T; Nagao M
ACS Chem Biol; 2015 Dec; 10(12):2794-804. PubMed ID: 26414848
[TBL] [Abstract][Full Text] [Related]
30. Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
Jöst C; Nitsche C; Scholz T; Roux L; Klein CD
J Med Chem; 2014 Sep; 57(18):7590-9. PubMed ID: 25148591
[TBL] [Abstract][Full Text] [Related]
31. 2-Sulfonylpyridines as Tunable, Cysteine-Reactive Electrophiles.
Zambaldo C; Vinogradova EV; Qi X; Iaconelli J; Suciu RM; Koh M; Senkane K; Chadwick SR; Sanchez BB; Chen JS; Chatterjee AK; Liu P; Schultz PG; Cravatt BF; Bollong MJ
J Am Chem Soc; 2020 May; 142(19):8972-8979. PubMed ID: 32302104
[TBL] [Abstract][Full Text] [Related]
32. Direct mapping of ligandable tyrosines and lysines in cells with chiral sulfonyl fluoride probes.
Chen Y; Craven GB; Kamber RA; Cuesta A; Zhersh S; Moroz YS; Bassik MC; Taunton J
Nat Chem; 2023 Nov; 15(11):1616-1625. PubMed ID: 37460812
[TBL] [Abstract][Full Text] [Related]
33. Lysine-Targeted Inhibitors and Chemoproteomic Probes.
Cuesta A; Taunton J
Annu Rev Biochem; 2019 Jun; 88():365-381. PubMed ID: 30633551
[TBL] [Abstract][Full Text] [Related]
34. Chemoproteomics-enabled covalent ligand screen reveals a cysteine hotspot in reticulon 4 that impairs ER morphology and cancer pathogenicity.
Bateman LA; Nguyen TB; Roberts AM; Miyamoto DK; Ku WM; Huffman TR; Petri Y; Heslin MJ; Contreras CM; Skibola CF; Olzmann JA; Nomura DK
Chem Commun (Camb); 2017 Jun; 53(53):7234-7237. PubMed ID: 28352901
[TBL] [Abstract][Full Text] [Related]
35. Chemoisosterism in the proteome.
Jalencas X; Mestres J
J Chem Inf Model; 2013 Feb; 53(2):279-92. PubMed ID: 23312010
[TBL] [Abstract][Full Text] [Related]
36. Statistical Analysis and Prediction of Covalent Ligand Targeted Cysteine Residues.
Zhang W; Pei J; Lai L
J Chem Inf Model; 2017 Jun; 57(6):1453-1460. PubMed ID: 28510428
[TBL] [Abstract][Full Text] [Related]
37. Machine Learning Models to Interrogate Proteome-Wide Covalent Ligandabilities Directed at Cysteines.
Liu R; Clayton J; Shen M; Bhatnagar S; Shen J
JACS Au; 2024 Apr; 4(4):1374-1384. PubMed ID: 38665640
[TBL] [Abstract][Full Text] [Related]
38. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
Hoffer L; Renaud JP; Horvath D
J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
[TBL] [Abstract][Full Text] [Related]
39. Medicinal Chemistry Projects Requiring Imaginative Structure-Based Drug Design Methods.
Moitessier N; Pottel J; Therrien E; Englebienne P; Liu Z; Tomberg A; Corbeil CR
Acc Chem Res; 2016 Sep; 49(9):1646-57. PubMed ID: 27529781
[TBL] [Abstract][Full Text] [Related]
40. Fragment-based covalent ligand discovery.
Lu W; Kostic M; Zhang T; Che J; Patricelli MP; Jones LH; Chouchani ET; Gray NS
RSC Chem Biol; 2021 Apr; 2(2):354-367. PubMed ID: 34458789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
